Andy McEwen

Andy McEwen

Auto-generated profile, based on publicly available information

Andy McEwen

National Centre for Smoking Cessation and Training , Dorchester , UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
DSDayyanah Sumodhee
Dayyanah Sumodhee
HWHannah Walsh
Hannah Walsh
LBLeonie Brose
Leonie Brose
AMAnn Mcneill
Ann Mcneill
AMAndy McEwen
Andy McEwen
MDMaría Duaso
María Duaso
Co-use of tobacco and cannabis is highly prevalent among cannabis users and is associated with poorer tobacco cessation outcomes. This study explored the barriers and enablers influencing stop-smoking practitioners’ ability to provide optimal support to co-users. Online semi-structured interviews were audio recorded. Interviewees (n = 20) were UK-based certified stop-smoking practitioners. An interview schedule informed by the “capability”, “opportunity”, “motivation” (COM-B) model was designed to explore participants’ perceived barriers and enablers in better supporting co-users to achieve abstinence of both substances or tobacco harm reduction. The transcripts were analyzed using framework analysis. Capability: Practitioners’ lack of knowledge and skills undermines their delivery of smoking cessation interventions to co-users. Interestingly, when cannabis is used for medicinal reasons, practitioners feel unable to provide adequate support. Opportunity: Service recording systems play an important role in screening for co-use and supporting co-users. When responding to clients’ specific needs and practitioners’ uncertainties, a positive therapeutic relationship and a support network of peers and other healthcare professionals are needed. Motivation: supporting co-users is generally perceived as part of practitioners’ roles but there are concerns that co-users are less likely to successfully stop smoking. Practitioners are willing to support co-users, but their lack of knowledge and access to an appropriate recording system are barriers to doing so. Having a supportive team and a positive therapeutic relationship is perceived as important. Identified barriers can be mostly addressed with further training to improve tobacco cessation outcomes for co-users.

1 August 2018 in Health Technology Assessment
Verified
Journal Article
Closed access
PAPaul Aveyard
Paul Aveyard
NLNicola Lindson
Nicola Lindson
STSarah Tearne
Sarah Tearne
RARachel Adams
Rachel Adams
KAKhaled Ahmed
Khaled Ahmed
SPSubhash Pokhrel
Subhash Pokhrel
Background: Nicotine preloading means using nicotine replacement therapy prior to a quit date while smoking normally. The aim is to reduce the drive to smoke, thereby reducing cravings for smoking after quit day, which are the main cause of early relapse. A prior systematic review showed inconclusive and heterogeneous evidence that preloading was effective and little evidence of the mechanism of action, with no cost-effectiveness data.Objectives: To assess (1) the effectiveness, safety and tolerability of nicotine preloading in a routine NHS setting relative to usual care, (2) the mechanisms of the action of preloading and (3) the cost-effectiveness of preloading.Design: Open-label randomised controlled trial with examination of mediation and a cost-effectiveness analysis.Setting: NHS smoking cessation clinics.Participants: People seeking help to stop smoking.Interventions: Nicotine preloading comprised wearing a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date. In addition, minimal behavioural support was provided to explain the intervention rationale and to support adherence. In the comparator group, participants received equivalent behavioural support. Randomisation was stratified by centre and concealed from investigators.Main outcome measures: The primary outcome was 6-month prolonged abstinence assessed using the Russell Standard. The secondary outcomes were 4-week and 12-month abstinence. Adverse events (AEs) were assessed from baseline to 1 week after quit day. In a planned analysis, we adjusted for the use of varenicline (Champix®; Pfizer Inc., New York, NY, USA) as post-cessation medication. Cost-effectiveness analysis took a health-service perspective. The within-trial analysis assessed health-service costs during the 13 months of trial enrolment relative to the previous 6 months comparing trial arms. The base case was based on multiple imputation for missing cost data. We modelled long-term health outcomes of smoking-related diseases using the European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) model.Results: In total, 1792 people were eligible and were enrolled in the study, with 893 randomised to the control group and 899 randomised to the intervention group. In the intervention group, 49 (5.5%) people discontinued preloading prematurely and most others used it daily. The primary outcome, biochemically validated 6-month abstinence, was achieved by 157 (17.5%) people in the intervention group and 129 (14.4%) people in the control group, a difference of 3.02 percentage points [95% confidence interval (CI) –0.37 to 6.41 percentage points; odds ratio (OR) 1.25, 95% CI 0.97 to 1.62;p = 0.081]. Adjusted for use of post-quit day varenicline, the OR was 1.34 (95% CI 1.03 to 1.73;p = 0.028). Secondary abstinence outcomes were similar. The OR for the occurrence of serious AEs was 1.12 (95% CI 0.42 to 3.03). Moderate-severity nausea occurred in an additional 4% of the preloading group compared with the control group. There was evidence that reduced urges to smoke and reduced smoke inhalation mediated the effect of preloading on abstinence. The incremental cost-effectiveness ratio at the 6-month follow-up for preloading relative to control was £710 (95% CI –£13,674 to £23,205), but preloading was dominant at 12 months and in the long term, with an 80% probability that it is cost saving.Limitations: The open-label design could partially account for the mediation results. Outcome assessment could not be blinded but was biochemically verified.Conclusions: Use of nicotine-patch preloading for 4 weeks prior to attempting to stop smoking can increase the proportion of people who stop successfully, but its benefit is undermined because it reduces the use of varenicline after preloading. If this latter effect could be overcome, then nicotine preloading appears to improve health and reduce health-service costs in the long term. Future work should determine how to ensure that people using nicotine preloading opt to use varenicline as cessation medication.Trial registration: Current Controlled Trials ISRCTN33031001.Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 22, No. 41. See the NIHR Journals Library website for further project information.

18 June 2023 in Addiction
Verified
Journal Article
Open access
TKTheodora Kotti
Theodora Kotti
EKEvangelos Katsampouris
Evangelos Katsampouris
MRMamta Ruparel
Mamta Ruparel
AMAndy McEwen
Andy McEwen
JDJennifer L. Dickson
Jennifer L. Dickson
SQSamantha L. Quaife
Samantha L. Quaife
Background and aims: Optimising smoking cessation (SC) referral strategies within lung cancer screening (LCS) could significantly reduce lung cancer mortality. This study aimed to measure acceptance of referral to SC support by either practitioner‐referral or self‐referral among participants attending a hospital‐based lung health check appointment for LCS as part of the Lung Screen Uptake Trial.Design: Single‐blinded two‐arm randomised controlled trial.Setting: England.Participants: Six hundred forty‐two individuals ages 60 to 75 years, who self‐reported currently smoking or had a carbon monoxide reading over 10 ppm during the lung health check appointment.Intervention and comparator: Participants were randomised (1:1) to receive either a contact information card for self‐referral to a local stop smoking service (SSS) (self‐referral, n = 360) or a SSS referral made on their behalf by the nurse or trial practitioner (practitioner‐referral, n = 329).Measurements: The primary outcome was acceptance of the practitioner‐referral (defined as participants giving permission for their details to be shared with the local SSS) compared with acceptance of the self‐referral (defined as participants taking the physical SSS contact information card to refer themselves to the local SSS).Findings: Half (49.8%) accepted the practitioner‐made referral to a local SSS, whereas most (88.5%) accepted the self‐referral. The odds of accepting the practitioner‐referral were statistically significantly lower (adjusted odds ratio = 0.10; 95% confidence interval = 0.06–0.17) than the self‐ referral. In analyses stratified by group, greater quit confidence, quit attempts and Black ethnicity were associated with increased acceptance within the practitioner‐referral group. There were no statistically significant interactions between acceptance by referral group and any of the participants’ demographic or smoking characteristics.Conclusions: Among participants in hospital‐based lung cancer screening in England who self‐reported smoking or met a carbon monoxide cut‐off, both practitioner‐referral and self‐referral smoking cessation strategies were highly accepted. Although self‐referral was more frequently accepted, prior evidence suggests practitioner‐referrals increase quit attempts, suggesting practitioner‐referrals should be the first‐line strategy within lung cancer screening, with self‐referral offered as an alternative.